- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06333483
A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) (CARLYSE)
A Single-Arm, Open-Label, Phase I Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients With Severe, Refractory Systemic Lupus Erythematosus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-arm, open-label Phase I Study to determine the safety, tolerability, and preliminary efficacy of obe-cel in patients with severe, refractory SLE. A maximum of n=12 patients will be treated in a maximum of 3 dose levels.
By using the Bayesian Optimal Interval (BOIN) design for overdose control, the Sponsor will review the Safety Review Committee (SRC) and Independent Data Monitoring Committee (IDMC) recommendation and determine if a dose level is suitable for a subsequent study.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Autolus Limited
- Phone Number: +44 (0) 203 911 4385
- Email: clinicaltrials@autolus.com
Study Locations
-
-
-
London, United Kingdom
- Recruiting
- University College London Hospitals NHS Foundation Trust
-
Contact:
- Maria Leandro
- Email: uclh.car-ttrials@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-Key Inclusion Criteria-
- Diagnosis of SLE fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus
- Positive for at least one of the following autoantibodies: antinuclear antibodies (ANA) at a titer of ≥ 1:80, or anti-dsDNA (≥ 30 IU/mL) or anti-Smith (> ULN), anti-histone or anti-chromatin (> ULN)
- Severe, refractory SLE
Exclusion Criteria:
-Key Exclusion Criteria-
SLE and Autoimmunity:
- Recurrent neuropsychiatric lupus or active, severe or unstable neuropsychiatric lupus within 2 years from screening
- Diagnosis of drug-induced SLE rather than idiopathic SLE
- Any acute, severe lupus-related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, making the patient ineligible for CD19 CAR T therapy as judged by the Investigator or Sponsor
- Significant, likely irreversible organ damage related to SLE (e.g., end-stage renal disease) that in the opinion of the Investigator renders CD19 CAR T cell therapy unlikely to benefit the patient
- Diagnosis of another non-SLE autoimmune disease (e.g., dermatomyositis, polymyositis, scleroderma, rheumatoid arthritis) or overlap syndrome
Medical History:
History or presence of: (Within 3 months before screening visit)
- Clinically relevant central nervous system (CNS) pathology such as epilepsy, paresis, aphasia, or stroke
- Evidence of deep venous thrombosis or pulmonary embolism
- History or presence of severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis
- Clinically significant, uncontrolled heart disease not due to SLE (New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled cardiac arrhythmia, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless the patient has a pacemaker) or a recent (within 12 months of screening) cardiac event
- Active or uncontrolled fungal, bacterial, viral (including COVID-19), or other infection requiring systemic antimicrobials for management
- Active or latent hepatitis B or active hepatitis C
- Human immunodeficiency virus, human T-cell leukemia virus (HTLV)-1, HTLV-2 or syphilis positive test at screening
- History of malignant neoplasms unless disease free for at least 24 months (basal cell or squamous cell carcinoma in situ, or in situ breast cancer on hormonal therapy allowed)
- History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant
- Pregnancy or lactating
Laboratory and Organ Function:
- Left ventricular ejection fraction < 45% (or < institutes lower limit of normal) confirmed by ECHO
- Oxygen saturation (SpO2) < 90% in the absence of oxygen support
Medications
- Prior treatment with anti-CD19 therapy (including bispecifics), adoptive T cell therapy or any prior gene therapy product (e.g., CAR T cell therapy)
- Immunization with a live or attenuated vaccine within 2 months of leukapheresis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AUTO1
|
Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities
Time Frame: Up to 28 days from obe-cel infusion
|
Percentage of patients receiving obe-cel who experience dose-limiting toxicities (DLTs)
|
Up to 28 days from obe-cel infusion
|
Adverse events
Time Frame: Up to Month 12
|
Adverse event (AE) type, frequency, severity, and relationship with obe-cel and lymphodepletion of AEs
|
Up to Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission rate according to Definition of Remission in SLE (DORIS)
Time Frame: Up to Month 12
|
Remission rate as specified by Definition of Remission in SLE (DORIS)
|
Up to Month 12
|
Response over time according to Definition of Remission in SLE (DORIS)
Time Frame: Up to Month 12
|
Response over time as specified by Definition of Remission in SLE (DORIS)
|
Up to Month 12
|
Time to response according to Definition of Remission in SLE (DORIS)
Time Frame: Up to Month 12
|
Time to response as specified by Definition of Remission in SLE (DORIS)
|
Up to Month 12
|
Change over time in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Time Frame: Up to Month 12
|
Change compared to baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.
The total score is the sum of all marked SLE-related descriptors.
A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.
|
Up to Month 12
|
Change over time in Physician's global assessment (PGA)
Time Frame: Up to Month 12
|
Change compared to baseline in physician's global assessment (PGA) of average SLE disease severity on a visual analog scale (VAS) between 0 and 3 where 0 represents no disease, 1 represents mild disease activity, 2 represents moderate disease activity, and 3 represents a severe disease activity (highest and most severe possible disease activity).
At least 10% change improvement or worsening in PGA to be clinically significant compared to baseline
|
Up to Month 12
|
Pharmacokinetics (maximum serum concentration [Cmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood
Time Frame: Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Detection of CAR T cells measured by PCR in the peripheral blood after obe-cel infusion
|
Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Pharmacokinetics (time to reaching maximum serum concentration [Tmax]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood
Time Frame: Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Detection of CAR T cells measured by PCR in the peripheral blood after obe-cel infusion
|
Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Pharmacokinetics (area under the curve [AUC]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood
Time Frame: Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Detection of CAR T cells measured by PCR in the peripheral blood after obe-cel infusion
|
Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Pharmacokinetics (last observed quantifiable concentration [Clast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood
Time Frame: Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Detection of CAR T cells measured by PCR in the peripheral blood after obe-cel infusion
|
Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Pharmacokinetics (time to reach last observed quantifiable concentration [Tlast]): Detection of CAR-T cells by polymerase chain reaction (PCR) in peripheral blood
Time Frame: Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Detection of CAR T cells measured by PCR in the peripheral blood after obe-cel infusion
|
Pre-infusion at Day -6, and at 9 timepoints post infusion between Days 1 and 28, followed by Month 2, Month 3 then 3 monthly to Month 12 and finally 6 monthly through study completion, up to a total of 3 years
|
Pharmacodynamics: B cell aplasia
Time Frame: Screening, pre-infusion Day -6, Day 1, Day 3, Day 28, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12 then 6 monthly through study completion, up to a total of 3 years
|
Depletion of circulating B cells in the peripheral blood
|
Screening, pre-infusion Day -6, Day 1, Day 3, Day 28, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12 then 6 monthly through study completion, up to a total of 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUTO1-SL1
- 2023-508236-60-00 (Ctis)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang UniversityRecruitingSystemic Lupus Erythematosus (SLE)China
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)Spain, Bulgaria, United States, China, Serbia, Mexico, Korea, Republic of, Chile, Argentina, Poland, Japan, Romania, Colombia, Hungary, Czechia, United Kingdom, Taiwan, Brazil, Israel, France
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
AmgenTerminatedActive Systemic Lupus ErythematosusKorea, Republic of, United States, Taiwan, Canada, Spain, Italy, Mexico, Japan, Turkey, Austria, Greece, Colombia, Switzerland, Poland, France, Bulgaria, Hong Kong, Russian Federation, Chile
Clinical Trials on Obecabtagene autoleucel (obe-cel)
-
Autolus LimitedRecruitingRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin LymphomaUnited Kingdom
-
Autolus LimitedActive, not recruitingRelapsed or Refractory B Cell Acute Lymphoblastic LeukemiaUnited States, United Kingdom, Spain
-
Ruijin HospitalNot yet recruitingB-NHL, Extranodal, TP53 Alterations, Bulky Mass
-
AdaptimmuneActive, not recruitingNeoplasmsUnited States, Canada, Spain, United Kingdom, Netherlands, France, Italy
-
Dana-Farber Cancer InstituteJanssen Research & Development, LLCRecruitingMultiple Myeloma | Smoldering Multiple MyelomaUnited States
-
Janssen Research & Development, LLCActive, not recruitingMultiple MyelomaUnited States, Belgium, Germany, Netherlands, Israel, Spain, Saudi Arabia, France